Patents Assigned to Vanderbilt Univeisily
  • Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus
    Patent number: 11660332
    Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 30, 2023
    Assignees: The Trustees of the University of Pennsylvania, The Johns Hopkins University, Vanderbilt Univeisily
    Inventors: Drew Weissman, George M. Shaw, Justin R. Bailey, Stuart C. Ray, James Crowe, Jr., Andrew Flyak